Lorusso D, Ferrandina G, Colombo N, et al. - Given a poor prognosis in correlation to increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC), researchers sought to report preliminary clinical data on the efficacy bevacizumab in EC both as a single agent and in combination with chemotherapy. In a phase II trial, either Carboplatin-Paclitaxel standard dose for 6–8 cycles or Carboplatin-Paclitaxel and Bevacizumab 15 mg/kg in combination with chemotherapy were provided to patients with advanced (FIGO stage III-IV) or recurrent EC; these treatments were maintained until disease progression or unacceptable toxicity. Outcomes revealed no increased PFS in correlation to receiving bevacizumab combined with chemotherapy vs chemotherapy in recurrent endometrial cancer. The patients in bevacizumab arm more frequently experienced cardiovascular events. However, the preliminary data indicate some efficacy of the antiangiogenic agent which justifies further exploration in a larger population with a better molecular characterization.